We share a passion for thinking in new and different ways. Our natural curiosity brings us closer to unlocking the potential of blood, transforming scientific understanding into practical application. We proudly offer an annual grant program to encourage academic discovery and recognize new practical application that fuels our ongoing quest to unlock the potential of blood.
One of our 2018 educational grants supported the 2018 University of Kansas Neuromuscular Review Course. These neuromuscular courses are designed for neurologists and other physicians treating neuromuscular disorders and provide an up-to-date review of clinical issues related to the diagnosis and treatment of neuromuscular diseases. Terumo BCT supported 10 courses in 2018 with our unrestricted educational grant.
The Advancing Apheresis Award is an educational grant of USD $10,000 to the organization or institution that best displays a dedication to advancing apheresis. In 2018, the sixth annual award focused on advancing peripheral venous access in red blood cell exchange procedures and was awarded to UHN Toronto, Canada.
We are committed to increasing our impact on patients’ lives. UHN’s leadership in this area will drive better outcomes for patients with sickle cell disease. With eventual publication and sharing of best practices, this effort has the potential to help enhance current standards of care for peripheral vascular access, so we can all better support this underserved patient population.
The grant will help UHN fund teaching programs along with the purchase of phantom arms for training and skills maintenance, the development of electronic training materials and the collection of data for analysis. UHN’s plan is to use the data and analysis in a publication demonstrating the outcomes of making peripheral ultrasound guided venous access the standard of care.
We have potential to spread these training efforts across UHN and to other apheresis nurses across Canada. Many people may benefit from this work, including patients with sickle cell disease and others needing apheresis treatments who struggle with peripheral access issues.